Cat. No.: HY-L199

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

83 Cited Publications

Customer Review

Based on 83 publication(s) in Google Scholar

Non-alcoholic fatty liver disease (NAFLD) is one of the most common liver diseases worldwide and is the primary liver manifestation of metabolic syndrome. The growth of NAFLD has coincided with the obesity epidemic. NAFLD is composed of excess lipid accumulation in the liver, causing steatotoxicity, and shows a wide range of histopathological abnormalities. NAFLD may progress from simple steatosis to Non-alcoholic steatohepatitis (NASH) with or without fibrosis (NASH), and eventually to cirrhosis and hepatocellular carcinoma. To date, very few drugs have been approved for marketing specifically for the treatment of NAFLD, so increased efforts to develop NAFLD drugs are necessary.

MCE designs a unique collection of 4,957 small molecules with definite or potential anti-NAFLD activity, which is an important tool for studying the pathological mechanism of NAFLD and developing drugs for NAFLD.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

PDF
Excel
SDF
Manual

Size

Price

Stock

Quantity

In-stock

(2-3 weeks)

Get a Quotation Now

In-stock

(2-3 weeks)

Get a Quotation Now

(2-3 weeks)

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Description & Advantages
Product Details
- Formulation
- Layout
- Container
- Storage
- Shipping
Publications (83)
Documentation
Composition

Description & Advantages

• A unique collection of 4,957 compounds with definite or potential non-alcoholic fatty liver disease (NAFLD) activity for high throughput screening (HTS) and high content screening (HCS).

• The compound library targets include Sirtuin, PPAR, NF-κB etc.

• A useful tool for the discovery of compounds for NAFLD.

• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

• Structurally diverse, bioactive, and cell permeable.

• More detailed compound information with structure, IC50, and other chemical & biological data.

• High purity and quality validated by NMR and LC/MS.

• All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 4,957 NAFLD-related compounds supplied as pre-dissolved solutions or solid.

Solution: 4,809 compounds supplied in 10 mM solution, 131 compounds supplied in 2 mM solution, 17 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage

-80°C

Shipping

Blue ice or dry ice